Log in

Relevant bibliographies by topics / MOG antibodies, neurofilament light chain, MOGAD

Contents

Journal articles
Dissertations / Theses

Academic literature on the topic 'MOG antibodies, neurofilament light chain, MOGAD'

Author: Grafiati

Published: 11 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'MOG antibodies, neurofilament light chain, MOGAD.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "MOG antibodies, neurofilament light chain, MOGAD"

1

S, Mariotto, Farinazzo A, Monaco S, et al. "Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status." Multiple Sclerosis Journal - Experimental, Translational and Clinical 3, no. 4 (2017): 205521731774309. http://dx.doi.org/10.1177/2055217317743098.

Full text

Abstract:

Background Neurofilament light chain (NF-L) levels reflect axonal damage in different conditions, including demyelinating disorders. Objectives We aimed to compare serum NF-L levels in patients with aquaporin-4 antibodies (AQP4-Ab), myelin oligodendrocyte antibodies (MOG-Ab) and seronegative cases with neuromyelitis optica spectrum disorders and related disorders. Methods We analysed AQP4-Ab and MOG-Ab with cell-based assay and NF-L with ultrasensitive electrochemiluminescence immunoassay. Results Median NF-L levels were increased in 25 AQP4-Ab-positive patients (59 pg/ml) as compared with 22

APA, Harvard, Vancouver, ISO, and other styles

2

Kim, Hyunjin, Eun-Jae Lee, Seungmi Kim, et al. "Serum biomarkers in myelin oligodendrocyte glycoprotein antibody–associated disease." Neurology - Neuroimmunology Neuroinflammation 7, no. 3 (2020): e708. http://dx.doi.org/10.1212/nxi.0000000000000708.

Full text

Abstract:

ObjectiveTo test the hypothesis that the pattern of serum biomarkers of disease activity and disability in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) will be different from those in neuromyelitis optica spectrum disorder (NMOSD) with anti–aquaporin-4 antibodies (AQP4-Abs).MethodsUsing ultrasensitive single-molecule array assays, we measured neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and tau in the sera of consecutive patients with MOGAD (n = 16) and NMOSD with AQP4-Ab (n = 33). Serum biomarker levels were compared between patients in r

APA, Harvard, Vancouver, ISO, and other styles

3

Dinoto, Alessandro, Elia Sechi, Eoin P. Flanagan, et al. "Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease." Frontiers in Neurology 13 (March 23, 2022). http://dx.doi.org/10.3389/fneur.2022.866824.

Full text

Abstract:

The term neuromyelitis optica spectrum disorder (NMOSD) describes a group of clinical-MRI syndromes characterized by longitudinally extensive transverse myelitis, optic neuritis, brainstem dysfunction and/or, less commonly, encephalopathy. About 80% of patients harbor antibodies directed against the water channel aquaporin-4 (AQP4-IgG), expressed on astrocytes, which was found to be both a biomarker and a pathogenic cause of NMOSD. More recently, antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG), have been found to be a biomarker of a different entity, termed MOG antibody-associ

APA, Harvard, Vancouver, ISO, and other styles

4

Horellou, Philippe, Lorraine Flet-Berliac, Carole Leroy, et al. "Early blood neurofilament light chain and myelin oligodendrocyte glycoprotein (MOG) antibodies levels associate with different disease course of MOG-associated disease in children." Brain Communications, March 15, 2023. http://dx.doi.org/10.1093/braincomms/fcad063.

Full text

Abstract:

Abstract Acquired demyelinating syndrome associated with myelin oligodendrocyte glycoprotein antibodies, named recently myelin oligodendrocyte glycoprotein associated disease, represent more than 27% of this pediatric syndrome. Relapses occur in 40% of them which may be associated with severe outcomes. Aiming to identify biomarker allowing to predict relapse, we measured both myelin oligodendrocyte glycoprotein antibodies and neurofilament light chain levels in blood samples of patients which is known to reflect axonal injuries in neurological diseases including demyelinating autoimmune disord

APA, Harvard, Vancouver, ISO, and other styles

5

Hyun, Jae-Won, So Yeon Kim, Yeseul Kim, et al. "Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: Longitudinal assessment of serum neurofilament light chain." Multiple Sclerosis Journal, December 30, 2021, 135245852110637. http://dx.doi.org/10.1177/13524585211063756.

Full text

Abstract:

To evaluate the occurrence of attack-independent neuroaxonal and astrocytic damage in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) levels were longitudinally measured in 102 sera using a single-molecule array assay. Sera from 15 adults with relapsing MOGAD with available longitudinal samples for the median 24-month follow-up and 26 age-/sex-matched healthy controls were analyzed. sNfL levels were significantly elevated in all clinical attacks, where the levels decreased below or

APA, Harvard, Vancouver, ISO, and other styles

6

Simone, Marta, Claudia Palazzo, Mariangela Mastrapasqua, et al. "Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes." Frontiers in Neurology 12 (November 11, 2021). http://dx.doi.org/10.3389/fneur.2021.754518.

Full text

Abstract:

Introduction: The relationship between serum neurofilament light chain (sNfL) and myelin oligodendrocyte glycoprotein antibody (MOG-Ab) status has not been yet investigated in children with the acquired demyelinating syndrome (ADS).Objective and Methods: The sNfL levels and MOG-Abs were measured by ultrasensitive single-molecule array and cell-based assay in a cohort of 37 children with ADS and negativity for serum anti-aquaporin 4 (AQP4) antibodies. The sNfL levels were compared in MOG-Ab+/MOG-Ab– and in two subgroups MOG-Ab+ with/without encephalopathy.Results: About 40% ADS resulted in MOG-

APA, Harvard, Vancouver, ISO, and other styles

7

Jarius, S., M. Ringelstein, K. Schanda, et al. "Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity—a potential diagnostic pitfall in patients with MOG-EM/MOGAD." Journal of Neurology, April 13, 2024. http://dx.doi.org/10.1007/s00415-024-12285-5.

Full text

Abstract:

Abstract Background Myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD) is the most important differential diagnosis of both multiple sclerosis and neuromyelitis optica spectrum disorders. A recent proposal for new diagnostic criteria for MOG-EM/MOGAD explicitly recommends the use of immunoglobulin G subclass 1 (IgG1)- or IgG crystallizable fragment (Fc) region-specific assays and allows the use of heavy-and-light-chain-(H+L) specific assays for detecting MOG-IgG. By contrast, the utility of MOG-IgG3-specific te

APA, Harvard, Vancouver, ISO, and other styles

8

Wendel, Eva-Maria, Annikki Bertolini, Lampros Kousoulos, et al. "Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome." Multiple Sclerosis Journal, March 14, 2022, 135245852210810. http://dx.doi.org/10.1177/13524585221081090.

Full text

Abstract:

Objective: To assess the diagnostic and prognostic potential of serum neurofilament light chain (sNfL) in children with first acquired demyelinating syndrome (ADS). Methods: We selected 129 children with first ADS including 19 children with myelin oligodendrocyte glycoprotein (MOG)-antibody associated disease (MOGAD), 36 MOG/AQP4-seronegative ADS, and 74 with multiple sclerosis (MS) from the BIOMARKER study cohort. All children had a complete set of clinical, radiological, laboratory data and serum for NfL measurement using a highly sensitive digital ELISA (SIMOA). A control group of 35 childr

APA, Harvard, Vancouver, ISO, and other styles

9

Wang, Xin, Yi Qu, Jiayu Fan, and Huiqiang Ren. "Serum NfL and EGFR/NfL ratio mRNAs as biomarkers for phenotype and disease severity of myelin oligodendrocyte glycoprotein IgG-associated disease." Frontiers in Immunology 15 (May 14, 2024). http://dx.doi.org/10.3389/fimmu.2024.1388734.

Full text

Abstract:

Background and purposeMyelin oligodendrocyte glycoprotein (MOG) IgG is frequently elevated in pediatric patients with acquired demyelinating syndrome (ADS). However, no specific biomarkers exist for phenotype classification, symptom severity, prognosis, and treatment guidance of MOG-IgG-associated disease (MOGAD). This study evaluated neurofilament light chain (NfL) and endothelial growth factor receptor (EGFR) mRNA expression levels in serum and cerebrospinal fluid (CSF) as potential biomarkers for MOGAD in Chinese children.MethodsThis was a cross-sectional and single-center study. We enrolle

APA, Harvard, Vancouver, ISO, and other styles

10

Mariotto, Sara, Sergio Ferrari, Daniela Alberti, et al. "Neurofilament Light Chain Levels in Patients with Antibodies to Myelin Oligodendrocyte Glycoprotein (MOG-Ab) (1783)." Neurology 94, no. 15_supplement (2020). http://dx.doi.org/10.1212/wnl.94.15_supplement.1783.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "MOG antibodies, neurofilament light chain, MOGAD"

1

Mariotto, Sara. "Neurofilament light chain levels in patients with antibodies to myelin oligodendrocyte glycoprotein (MOG-Abs)." Doctoral thesis, 2020. http://hdl.handle.net/11562/1016187.

Full text

Abstract:

Objective: to assess neurofilament light chain (NfL) concentration in MOG-Ab-positive patients according to clinical/paraclinical characteristics and to evaluate intraindividual changes over time. Background: NfL is a marker of axonal injury, increased in serum/CSF of patients with several neurological disorders in correlation with clinical and radiological activity. As a consequence, NfL could be a useful biomarker to monitor disease activity in MOG-Ab-related inflammatory conditions, where the course is highly heterogeneous and unpredictable. Design/methods: sera and available (n=17) CSF sam

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!